Fig. 4
2B4.z-NK cells show stronger anti-T-ALL activity in vivo. a Jurkat-luc2 cells were seeded in 96-well plates at 1.6 × 106, 4 × 105, 1 × 105, and 2.5 × 104, 1.5 μl of 10 mg/ml D-Luciferin was added per well, and then bioluminescent images were obtained by using Caliper IVIS Lumina II. Left panel: representative bioluminescence images of Jurkat-luc2 cells; right panel: correlation analysis of bioluminescence signals and cell numbers (goodness of fit; r2 = 0.9935; p = 0.0033; N, number). b Schematic diagram of the treatment regimen. Mice were intravenously injected with 3 × 106 Jurkat-luc2 cells. Nine days after transplantation, mice were divided into four treatment groups according to the average radiance of the bioluminescent imaging: group PBS, group VEC-NK, group BB.z-NK, and group 2B4.z-NK. Mice were respectively intravenously administered with PBS, 5 × 106 cells of either VEC-NK, BB.z-NK, or 2B4.z-NK cells at day 10, day 20, and day 26. c Statistical analysis of the bioluminescence intensity of each treatment group measured at different days (n = 6; two-way ANOVA; *p < 0.05; ***p < 0.001; n.s., no significance). d Representative bioluminescence images of mice. e Body weight of each treatment group measured at different days (n = 6; two-way ANOVA; *p < 0.05; n.s., no significance). f Kaplan-Meier survival curves for mice (n = 6; log-rank test; *p < 0.05; ***p < 0.001;). g Representative flow cytometry analysis showing the proportion of CD45+CD5+ leukemia blasts in bone marrow, spleen, and liver of NSG mice. h Representative H&E staining of bone marrow, spleen, and liver of NSG mice.VEC: VEC-NK; BB.z: BB.z-NK; 2B4.z: 2B4.z-NK